SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices surge to new highs, driven by a weakening dollar and global economic uncertainty. Community discussions revolve around whether this rally is sustainable or indicative of a larger market bubble, with some anticipating a significant correction while others remain bullish due to geopolitical tensions and potential Federal Reserve actions.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as traders debate whether it's a dip-buying opportunity or if further downside is expected, particularly with Bitcoin's recent volatility and its exclusion from the S&P 500. Community sentiment is mixed, with some seeing a potential rebound and others expressing concerns about its correlation to Bitcoin and dilution. Discussions include potential price targets, technical analysis, and overall confidence in the company's long-term prospects.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining ($CIFR) is trending amid community discussion around its shift towards AI/HPC infrastructure and speculation about potential deals with major hyperscalers like Google and Oracle. Some traders are debating whether recent gains are sustainable, while others point to the company's low energy costs and significant power capacity as bullish indicators. Community members are also closely watching for a potential short squeeze and reacting to analyst price target upgrades.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending amid discussions around potential HR downsizing and restructuring efforts, possibly linked to increased AI spending. The community is analyzing technical indicators for potential trading strategies, while also debating the company's valuation and future growth prospects in a competitive tech landscape. Some traders are expressing frustration with the stock's recent performance.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending due to long-term revenue forecasts and AI growth plans revealed at Dreamforce, with bulls optimistic about FY2030 targets of $60B+ and a recent $7B buyback program. However, some community members express concerns about execution and management, noting the stock's recent underperformance compared to peers and CEO share sales. Discussions also involve Salesforce's AI integrations with Google and OpenAI.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a significant price drop, sparking debates about overvaluation and potential offerings. The community is discussing whether this marks the start of a larger correction in the quantum computing sector, with some traders anticipating further declines while others see a buying opportunity. Concerns are also circulating around the CEO's past stock sales.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders react to market volatility and potential trade tensions, with community members actively discussing hedging strategies and positioning for potential market downturns. The ETF's price action and its relationship to broader market indices like the SPY are also being closely monitored. Some traders express concerns about the ETF's management and performance relative to the VIX.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid concerns about regional banks and their potential exposure to sour loans, sparking fears of a broader market downturn. The community is closely watching the VIX and potential bearish signals, while some traders are pointing to gold's rise as a safe-haven asset. Discussions also revolve around potential market manipulation and the impact of economic policies.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

PRAX is trending due to positive Phase 3 trial results for its essential tremor treatment, sparking significant community discussion about its potential and future prospects. While some traders are optimistic about the stock's potential for further gains, others are wary of a potential offering and are considering short positions, contributing to the volatility and heightened interest in the stock. Analyst upgrades and potential peak sales are being heavily discussed.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

Fueled by a recent $3.2B debt raise supported by Google for AI and HPC infrastructure, TeraWulf ($WULF) is trending as the community debates its future. Bulls anticipate a potential short squeeze due to high short interest and significant call option activity, while bears are wary of the company's debt load and potential market volatility. Discussions also involve the company's shift from Bitcoin mining to AI data centers and the implications of this transition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer

Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer. 

Can Auvelity Drive Axsome's Growth Through the Rest of 2025?

AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.

Here's Why JAZZ Stock Is an Unconventional Cannabis Investment

Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock

Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Jazz Pharmaceuticals experienced increased retail chatter on Wednesday after the U.S. Food and Drug Administration (FDA) granted accelerated approval to Modeyso (dordaviprone)&nbsp;for the treatment of a specific form of brain tumor.The drug is approved to treat adult and pediatric patients aged one year and older with diffuse midline glioma carrying an H3 K27M mutation, following progression after prior therapy. Continued approval may depend on confirmatory results from the Phase 3 ACTION trial.Modeyso is the first FDA-approved therapy for this rare and aggressive brain tumor, which affects an estimated 2,000 people in the U.S. annually, many of them children and young adults, according to the company.The oral, once-weekly capsule is expected to be commercially available in the coming weeks. The FDA based its decision on data from 50 patients enrolled across five open-label studies. About 1 in 5 patients responded to treatment, with responses lasting a median of just over 10 months.&nbsp;Among those who responded, nearly three-quarters saw benefits for at least six months, and more than a quarter maintained their response for at least a year.Patrick Wen of Dana-Farber Cancer Institute called the approval a “major turning point in neuro-oncology,” noting that Modeyso introduces a new treatment option for a population with limited choices.&nbsp;About a third of glioma patients in the trial experienced serious side effects on Modeyso, including hydrocephalus, seizures, vomiting, and muscle weakness. Fatigue, nausea, and headaches were the most common complaints.Separately, Truist Securities reduced its price target on Jazz Pharmaceuticals to $200 from $230, citing slower momentum in Epidiolex and cancer therapies such as Rylaze and Zepzelca.&nbsp;In the second quarter, Rylaze revenue dropped 7% to $100.7 million, and Zepzelca sales slipped 8% to $74.5 million. Epidiolex posted modest 2% growth to $251.7 million.&nbsp;Truist noted that the company’s total revenue was propped up by strong momentum in the oxybate franchise, where the lead drug, Xywav, rose 13% to $415.3 million. However, it flagged potential headwinds from two upcoming non-oxybate narcolepsy treatments nearing FDA review.On Stocktwits, retail sentiment for Jazz Pharmaceuticals was ‘extremely bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/JAZZ">Jazz Pharmaceuticals’ stock</a> has declined 14.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jazz Pharmaceuticals (JAZZ) experienced increased retail chatter on Wednesday after the U.S. Food and Drug Administration (FDA) granted accelerated approval to Modeyso  (Photo credit: Getty Images)

Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor

The approval was based on pooled data from 50 patients in five open-label trials, showing an overall response rate of 22%, with a median response duration of 10.3 months.

Equity

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.

Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$134.25
Prev Close	$135.80
Open	$136.03
Dividend Yield	0.00%
50-Day Moving Average	$126.83
Beta	0.75
Avg. Volume	710,830.67
PE Ratio	-20.13

52-Week High	$148.06
52-Week Low	$95.49
Market Capitalization	$8.24B
EPS (Annual)	$8.65
Price to Book	2.22
Revenue Per Employee	$1.45M
Enterprise Value/EBITDA	N/A

JAZZ
Jazz Pharmaceuticals plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JAZZ News

JAZZJazz Pharmaceuticals plc